Macrogen and Ultima Genomics Hold Joint Symposium for Popularization of AI Genome Analysis - 벤처스퀘어

– Implementation of low-cost, high-efficiency genomic analysis based on the ultra-high-throughput NGS platform 'UG200' – Presenting a strategy to build an integrated BioAI ecosystem connecting data generation, AI analysis, and clinical application Global AI genomics analysis company Macrogen held the 'BioAI and Genomics Analysis Symposium' jointly with genomics analysis platform companies Ultima Genomics and Twist Bioscience and the Korea Biotechnology Industry Association at the Conrad Hotel in Yeouido, Seoul on the 2nd. This symposium served as a venue to share the achievements of technological collaboration aimed at lowering structural cost barriers to genomic analysis and ushering in the era of 'BioAI,' which combines data and AI. BioAI is a concept that integrates bio-data, such as genomics, with artificial intelligence for disease prediction and personalized treatment, and it is rapidly gaining attention in the field of precision medicine. Approximately 40 key researchers and business leaders driving the domestic bio industry attended the event. Lowering costs and raising efficiency with UG200… Accelerating the establishment of a global BioAI ecosystem At this event, Macrogen highlighted the synergy created by combining its genomic analysis capabilities with Ultima Genomics' ultra-high-throughput NGS platform, 'UG200'. UG200 is a platform capable of rapidly generating large-scale genomic data, characterized by lowering analysis costs compared to existing methods while simultaneously increasing data processing efficiency. The two companies plan to accelerate innovation across precision medicine—including disease prediction, personalized treatment, and new drug development collaboration—by combining vast amounts of genomic data with AI technology. They presented a vision to expedite the popularization of genomic analysis by establishing an integrated BioAI-based ecosystem that spans from data generation to AI analysis and clinical application. During the event, which consisted of a total of five sessions, Shin Sang-yoon, Head of Technology Strategy at Macrogen, delivered a keynote speech outlining strategies for securing and analyzing large-scale genomic data through the establishment of a genome foundry, as well as directions for expanding the application of precision medicine. In the subsequent sessions, case studies of BioAI research based on the UG200 platform, the development of AI-based disease prediction models, global research collaborations, and data utilization strategies were shared. “The collaboration with Ultima Genomics goes beyond a technology partnership and is a process of making the BioAI ecosystem a reality by drastically lowering the cost of genomic analysis and connecting it to AI analysis,” said Macrogen Chairman Seo Jeong-seon. “We will grow the ecosystem together so that more people can predict diseases and manage their health based on their genomic information.” You must be logged in to post a comment.